NYSE:NNVC NanoViricides (NNVC) Stock Forecast, Price & News $1.10 -0.03 (-2.65%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$1.10▼$1.1950-Day Range$1.05▼$1.6352-Week Range$1.04▼$3.88Volume19,129 shsAverage Volume37,383 shsMarket Capitalization$12.80 millionP/E RatioN/ADividend YieldN/APrice Target$5.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media NanoViricides MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside377.3% Upside$5.25 Price TargetShort InterestHealthy2.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector760th out of 981 stocksPharmaceutical Preparations Industry362nd out of 463 stocks 3.5 Analyst's Opinion Consensus RatingNanoViricides has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.25, NanoViricides has a forecasted upside of 377.3% from its current price of $1.10.Amount of Analyst CoverageNanoViricides has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.90% of the float of NanoViricides has been sold short.Short Interest Ratio / Days to CoverNanoViricides has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in NanoViricides has recently decreased by 21.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNanoViricides does not currently pay a dividend.Dividend GrowthNanoViricides does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NNVC. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for NanoViricides this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for NNVC on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added NanoViricides to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NanoViricides insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of NanoViricides is held by insiders.Percentage Held by InstitutionsOnly 11.43% of the stock of NanoViricides is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of NanoViricides is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NanoViricides is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNanoViricides has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NanoViricides (NYSE:NNVC) StockNanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.Read More Receive NNVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter. Email Address NNVC Stock News HeadlinesJune 1, 2023 | americanbankingnews.comNanoViricides (NYSE:NNVC) Receives New Coverage from Analysts at StockNews.comMay 31, 2023 | finance.yahoo.comNanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ETJune 8, 2023 | Behind the Markets (Ad)[Strong Buy Alert] Is this laser stock in your portfolio?🚨 [Strong Buy Alert] Is this laser stock in your portfolio? There are very few opportunities like this in today's bear market... But our analysts identified a tiny defense company landing billions of dollars in contracts every year.May 23, 2023 | americanbankingnews.comNanoViricides (NYSEAMERICAN:NNVC) Stock Passes Below 50 Day Moving Average of $1.30May 19, 2023 | proactiveinvestors.comBig box retailers lead mixed earnings week as consumers shift focus from goods to experiencesMay 16, 2023 | proactiveinvestors.comNanoViricides ends fiscal 3Q with strong cash runway to begin clinical trials of broad-spectrum COVID drugMay 16, 2023 | finanznachrichten.deNanoViricides, Inc.: NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to BeginMay 16, 2023 | finance.yahoo.comNanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to BeginJune 8, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 16, 2023 | americanbankingnews.comNanoViricides (NYSE:NNVC) Coverage Initiated by Analysts at StockNews.comMay 9, 2023 | americanbankingnews.comNanoViricides (NYSE:NNVC) Now Covered by StockNews.comMay 4, 2023 | finance.yahoo.comNanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York CityMay 2, 2023 | americanbankingnews.comNanoViricides (NYSE:NNVC) Earns Sell Rating from Analysts at StockNews.comApril 27, 2023 | americanbankingnews.comStockNews.com Begins Coverage on NanoViricides (NYSE:NNVC)April 25, 2023 | finance.yahoo.comNanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug IngredientApril 19, 2023 | msn.comEF Hutton Reiterates NanoViricides (NNVC) Buy RecommendationApril 19, 2023 | americanbankingnews.comNanoViricides (NYSE:NNVC) Coverage Initiated at StockNews.comApril 19, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on NanoViricides (NYSEAMERICAN:NNVC)April 17, 2023 | finance.yahoo.comNanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug CandidateApril 12, 2023 | proactiveinvestors.comNanoViricides using unique technology platform to fight against VirusesApril 10, 2023 | finance.yahoo.comNNVC: NanoViricides Technology Ready to Enter the ClinicApril 4, 2023 | finance.yahoo.comNanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug CandidatesJanuary 5, 2023 | finanznachrichten.deNanoViricides, Inc. to Present at the Biotech Showcase 2023 Conference in San Fransisco on January 9th at 10:30am PTJanuary 4, 2023 | finance.yahoo.comNanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PTDecember 25, 2022 | finance.yahoo.comNanoViricides, Inc. (NNVC) Stock Historical Prices & Data - Yahoo FinanceDecember 5, 2022 | finance.yahoo.comNanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ETNovember 15, 2022 | finanznachrichten.deFinancialnewsmedia.com: Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027See More Headlines NNVC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NNVC Company Calendar Last Earnings11/15/2021Today6/07/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:NNVC CUSIPN/A CIK1379006 Webwww.nanoviricides.com Phone(203) 937-6137Fax203-859-5095EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$5.25 High Stock Price Forecast$5.25 Low Stock Price Forecast$5.25 Forecasted Upside/Downside+377.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,110,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.87% Return on Assets-32.19% Debt Debt-to-Equity RatioN/A Current Ratio28.46 Quick Ratio28.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book0.55Miscellaneous Outstanding Shares11,640,000Free Float11,123,000Market Cap$12.80 million OptionableOptionable Beta1.10 Key ExecutivesAnil R. DiwanExecutive Chairman, President & CEOMeeta R. VyasChief Financial & Accounting OfficerRandall W. BartonChief Scientific OfficerJayant TatakeVice President-Research & DevelopmentKey CompetitorsEvelo BiosciencesNASDAQ:EVLOIndaptus TherapeuticsNASDAQ:INDPNeuroBo PharmaceuticalsNASDAQ:NRBOShuttle PharmaceuticalsNASDAQ:SHPHVascular BiogenicsNASDAQ:VBLTView All Competitors NNVC Stock - Frequently Asked Questions Should I buy or sell NanoViricides stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoViricides in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NNVC shares. View NNVC analyst ratings or view top-rated stocks. What is NanoViricides' stock price forecast for 2023? 1 Wall Street research analysts have issued 12 month price targets for NanoViricides' stock. Their NNVC share price forecasts range from $5.25 to $5.25. On average, they expect the company's stock price to reach $5.25 in the next twelve months. This suggests a possible upside of 377.3% from the stock's current price. View analysts price targets for NNVC or view top-rated stocks among Wall Street analysts. How have NNVC shares performed in 2023? NanoViricides' stock was trading at $1.11 at the beginning of the year. Since then, NNVC shares have decreased by 0.9% and is now trading at $1.10. View the best growth stocks for 2023 here. Are investors shorting NanoViricides? NanoViricides saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 323,800 shares, a decrease of 21.0% from the April 30th total of 410,100 shares. Based on an average daily volume of 42,400 shares, the short-interest ratio is currently 7.6 days. Currently, 2.9% of the company's stock are sold short. View NanoViricides' Short Interest. How were NanoViricides' earnings last quarter? NanoViricides, Inc. (NYSE:NNVC) announced its quarterly earnings data on Monday, November, 15th. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.03. When did NanoViricides' stock split? Shares of NanoViricides reverse split before market open on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is NanoViricides' stock symbol? NanoViricides trades on the New York Stock Exchange (NYSE) under the ticker symbol "NNVC." How do I buy shares of NanoViricides? Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NanoViricides' stock price today? One share of NNVC stock can currently be purchased for approximately $1.10. How much money does NanoViricides make? NanoViricides (NYSE:NNVC) has a market capitalization of $12.80 million. The company earns $-8,110,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. How can I contact NanoViricides? NanoViricides' mailing address is 1 Controls Drive, Shelton CT, 06484. The official website for the company is www.nanoviricides.com. The company can be reached via phone at (203) 937-6137, via email at clyburn@tradigitalir.com, or via fax at 203-859-5095. This page (NYSE:NNVC) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.